Search
Browse
Statistics
Feeds

Ligand-specific activation trajectories dictate GPCR signalling in cells

[thumbnail of Publisher's Version]
Preview
PDF (Publisher's Version) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
23MB
[thumbnail of Supplementary Information incl. Source Data] Other (Supplementary Information incl. Source Data)
11MB

Item Type:Article
Title:Ligand-specific activation trajectories dictate GPCR signalling in cells
Creators Name:Thomas, Romy, Jacoby, Pauline S., De Faveri, Chiara, Derieux, Cécile, Liebing, Aenne-Dorothea, Melkes, Barbora, Martini, Hans-Joachim, Bermúdez, Marcel, Stäubert, Claudia, Lohse, Martin J., Coin, Irene and Bock, Andreas
Abstract:G-protein-coupled receptors (GPCRs) are key mediators of cell communication and represent the most important class of drug targets. Biophysical studies with purified GPCRs in vitro have suggested that they exist in an equilibrium of distinct inactive and active states, which is modulated by ligands in an efficacy-dependent manner. However, how efficacy is encoded and whether multiple receptor states occur in living cells remain unclear. Here we use genetic code expansion and bioorthogonal labelling to generate a panel of fluorescence-based biosensors for a prototypical GPCR, the M(2) muscarinic acetylcholine receptor (M(2)R). These biosensors enable real-time monitoring of agonist-promoted conformational changes across the receptor’s extracellular surface in intact cells. We demonstrate that different agonists produce equilibria of at least four distinct active states of the G-protein-bound M(2)R, each with a different ability to activate G proteins. The formation of these M(2)R–G-protein complexes occurs over 0.2–5 s along trajectories that involve both common and ligand-specific conformational changes and appear to determine G-protein selectivity. These observations reveal the molecular nature of ligand efficacy in intact cells. Selectively exploiting such different GPCR activation trajectories and conformational equilibria may open new avenues for GPCR drug discovery.
Source:Nature
ISSN:0028-0836
Publisher:Nature Publishing Group
Date:14 January 2026
Official Publication:https://doi.org/10.1038/s41586-025-09963-3
PubMed:View item in PubMed
Related to:

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library